As obesity, diabetes, and other chronic illnesses continue to rise across the world, leaders from the pharmaceutical industry, nutrition science, regulation, and investment sectors gathered in Mumbai this month to explore a question that could shape the future of healthcare: can responsible nutrition become a proven tool for preventing disease rather than simply treating it?

The fifth edition of Nutrify Today's C-Suite Sumflex concluded at Trident Oberoi, Mumbai, on June 5 after bringing together more than 150 global decision-makers from pharmaceutical companies, regulatory agencies, venture capital firms and ingredient manufacturers. Delegates increasingly described the gathering as the "Davos of Nutraceuticals", reflecting its growing influence in shaping discussions around the global nutrition economy.

The summit came at a time when scientific evidence is strengthening the case for preventive healthcare. Research published in leading journals, including The Lancet and Nature Medicine, has shown that obesity, poor diets, and metabolic disorders are major drivers of heart disease, diabetes, and several cancers. According to the World Health Organization, obesity rates have more than doubled among adults worldwide since 1990, creating an urgent need for solutions that go beyond medicines alone.

That urgency was reflected in discussions around GLP-1 therapies, a new class of obesity medicines that help regulate appetite and blood sugar levels. Experts noted that while these drugs are transforming treatment, nutrition remains essential for maintaining long-term health and improving patient outcomes.

"GLP-1 therapies are reshaping the global conversation around obesity, metabolic health, and chronic disease management. As healthcare evolves, nutrition is becoming an essential partner in improving patient outcomes, supporting adherence, and enabling long-term health transformation," said Vikrant Shrotriya, Managing Director, Novo Nordisk India.

Participants included leaders from Novo Nordisk, MSD, Mankind Pharma, Torrent Pharma, Dr Reddy's-Nestlé Health Science, Reckitt, Sanofi, the Food Safety and Standards Authority of India (FSSAI), the Maharashtra Food and Drug Administration, the Indian Pharmaceutical Alliance and OPPI, alongside investors and ingredient innovators from India and overseas.

One of the summit's most discussed sessions was "The Master Formulator Show", which highlighted formulation scientists. These specialists combine botanical ingredients, clinical evidence and manufacturing expertise to create products that meet global quality standards.

"The Master Formulator Show put scientists back at the centre of the industry, where they belong," said Shafiulla Hirehal Nuruddin, the managing director of Greenspace Herbs. "India's botanical edge will only become global brands if we celebrate the people who can turn a plant into a proven product."

For Nutrify Today Founder and Chief Catalyst Amit Srivastava, the event reflects a broader transformation.

"When we started, the Indian nutraceutical industry didn't have a room of its own. Five editions later, it has a global one," he said. "If Davos is where the world's economy meets, this is fast becoming where the world's nutrition economy chooses to meet."

The Mumbai gathering also followed the launch of Nutrify Today Eurasia Sumflex in Tashkent, Uzbekistan, which attracted nearly 3,000 participants and sought to strengthen collaboration across emerging health markets.

"Uzbekistan sees responsible nutrition as a bridge, not a border," said H.E. Abdulla Azizov, Chairman of the Medical and Pharmaceutical Industry Development Agency and First Deputy Minister of Health, Republic of Uzbekistan.

As artificial intelligence, pharmaceutical innovation and nutrition science increasingly intersected, industry leaders left Mumbai with a shared message: evidence-based nutrition is moving from the margins into the mainstream. For millions facing lifestyle diseases, that shift could influence not only what medicines they take, but also how they eat, age and stay healthy in the years ahead.